CAR-T success in patient with three autoimmune diseases
A patient with severe autoimmune hemolytic anemia, immune thrombocytopenia, and antiphospholipid antibody syndrome has been successfully treated with CAR-T therapy, achieving treatment-free remission and regaining the ability to lead an almost normal life.
For the first time, scientists have successfully used CAR-T therapy to treat a patient suffering from three life-threatening autoimmune diseases that had resisted over a decade of conventional treatments. The patient, a 47-year-old woman, has now been in remission for a year without requiring additional therapies.
The patient’s conditions included autoimmune hemolytic anemia (AIHA), where the immune system destroys red blood cells; immune thrombocytopenia (ITP), which causes platelet destruction and increases bleeding risk; and antiphospholipid antibody syndrome, a disorder that raises the risk of dangerous blood clots. These diseases had resisted all standard treatments, including antibody treatments, steroids and immune-suppressing medications, leaving the patient reliant on daily blood transfusions and blood thinners.
Emerging research has highlighted the potential of CAR-T therapy to reset dysregulated B cells in autoantibody-driven autoimmune diseases by targeting CD19, a protein expressed on the surface of B cells. In fact, the research team has previously demonstrated the efficacy of CD19-directed CAR-T therapy in refractory systemic lupus erythematosus and systemic sclerosis.
To address the patient’s complex case, the research team extracted her T cells and genetically engineered them to CD19-directed CARs. This enabled the CAR-T cells to selectively bind to and destroy the B cells driving her autoimmune diseases.
eBook: CAR-T therapy for autoimmune diseases
This eBook features a collection of articles exploring the potential of CAR-T therapy in autoimmune medicine, illuminating both current achievements and future possibilities in this field.
“The treatment was extremely efficient in getting rid of all three autoimmune conditions at once,” said corresponding author Fabian Müller of the University Hospital of Erlangen in Germany. “After being sick for more than a decade, the patient is now in treatment-free remission and able to return to an almost normal life. This therapy significantly improved her quality of life.”
Within a week of treatment, the patient no longer required blood transfusions. By the third week, her hemoglobin levels had doubled and returned to normal, indicating her immune system had stopped attacking red blood cells. Her platelet counts stabilized and the dangerous antiphospholipid antibodies disappeared. The therapy effectively reset her immune system, as her B cells regenerated months later as naive, healthy cells.
While the patient remains in remission a year after treatment, she has experienced mild side effects, including lower white blood cell counts and slightly elevated liver enzymes. However, the team believes these issues are likely due to years of prior treatments rather than the CAR-T therapy itself.
The success of this case suggests that CAR-T therapy could be a game-changer for patients with severe autoimmune diseases, particularly if used earlier in the disease process. “If we can intervene sooner, we may be able to stop the disease process, avoid organ damage, and give patients their lives back,” said Müller.
